Skip to main content
Back
TDVXF logo

Tobii Dynavox AB (publ)

Data quality: 100%
TDVXF
OTC Healthcare Medical - Instruments & Supplies
$8.68
▼ $0.32 (-3.56%)
Mkt Cap: 916.19M
Day Range
$8.50 $9.00
52-Week Range
$5.00 $13.55
Volume
700
50D / 200D Avg
$9.74 / $11.06
Prev Close
$9.00

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 5.5 0.4
P/B 1.5 2.9
ROE % 31.4 3.8
Net Margin % 6.7 3.9
Rev Growth 5Y % 29.7 10.0
D/E 1.8 0.2

Key Takeaways

Revenue grew 29.72% annually over 5 years — strong growth
ROE of 31.41% indicates high profitability
Negative free cash flow of -8.00M
P/E of 5.52 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4.62%
Capital efficient — spends only 8.31% of revenue on capex

Growth

Revenue Growth (5Y)
29.72%
Revenue (1Y)25.10%
Earnings (1Y)13.70%
FCF Growth (3Y)N/A

Quality

Return on Equity
31.41%
ROIC11.16%
Net Margin6.73%
Op. Margin10.30%

Safety

Debt / Equity
1.83
Current Ratio1.57
Interest Coverage5.42

Valuation

P/E Ratio
5.52
P/B Ratio1.52
EV/EBITDA7.19
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 25.10% Revenue Growth (3Y) 23.66%
Earnings Growth (1Y) 13.70% Earnings Growth (3Y) 26.28%
Revenue Growth (5Y) 29.72% Earnings Growth (5Y) 53.63%
Profitability
Revenue (TTM) 2.47B Net Income (TTM) 166.00M
ROE 31.41% ROA 6.71%
Gross Margin 68.42% Operating Margin 10.30%
Net Margin 6.73% Free Cash Flow (TTM) -8.00M
ROIC 11.16% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.83 Current Ratio 1.57
Interest Coverage 5.42 Dividend Yield 0.00%
Valuation
P/E Ratio 5.52 P/B Ratio 1.52
P/S Ratio 0.37 PEG Ratio 4.96
EV/EBITDA 7.19 Dividend Yield 0.00%
Market Cap 916.19M Enterprise Value 1.83B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.47B 1.97B 1.61B 1.22B 871.20M
Net Income 166.00M 146.00M 104.10M 48.60M 29.80M
EPS (Diluted) 1.56 1.37 0.98 0.46 0.30
Gross Profit 1.69B 1.36B 1.09B 787.80M 570.20M
Operating Income 254.00M 228.50M 154.80M 82.30M 60.00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.47B 2.00B 1.69B 1.32B 1.15B
Total Liabilities 1.87B 1.54B 1.39B 1.11B 1.01B
Shareholders' Equity 603.00M 454.00M 297.80M 210.60M 139.50M
Total Debt 1.10B 791.00M 773.30M 628.30M 606.70M
Cash & Equivalents 195.00M 133.00M 161.10M 106.80M 197.30M
Current Assets 1.08B 813.30M 633.40M 487.60M 446.00M
Current Liabilities 686.00M 630.00M 538.80M 425.00M 305.90M

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#111 of 616
64
Custom Contrarian Investing (David Dreman)
#66 of 658
67

Recent Activity

Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Contrarian Investing (David Dreman)
Mar 24, 2026